MedPath

BE-STRONG HCM: Biomarkers, Exercise Stress Testing, and MRI to Obtain New InsiGhts in Hypertrophic CardioMyopathy

Recruiting
Conditions
a thickened heart muscle based on genetic predisposition
Hypertrophic cardiomyopathy
10028593
10083624
Registration Number
NL-OMON35538
Lead Sponsor
niversitair Medisch Centrum Sint Radboud
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

•Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC guidelines;
•Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy (pre-clinical HCM patients);
•Age >= 18 years;
•Able to comply with the protocol;
•Written informed consent.

Exclusion Criteria

•Known significant epicardial coronary artery disease;
•Patients with LVH in the clinical setting of other disorders that explain the myocardial hypertrophy (amyloidosis, MELAS, Anderson-Fabry, WPW etc.);
•Heart failure NYHA class III-IV;
•Patients with known hemodynamic instability or syncope during exercise due to left ventricular
outflow gradient or occurrence of ventricular arrhythmia;
•History of PTSMA (percutaneous transluminal septal myocardial ablation) or Morrow myectomy;
•Patients not able to complete a bicycle test;
•Any contraindication to MR imaging (MR imaging is not obligatory for assessment of the primary objective, therefore relative exclusion criterion);
•Recent (within 30 days) admittance to the hospital for any cardiac reason (myocardial infarction, heart failure, cardiac arrhythmia, etc.);
•Severe renal insufficiency (eGFR < 30 ml/min);
•Any other condition which, in the opinion of the investigator, may pose a significant hazard to the subject if he or she participates in the present study.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Proportion of patients (pre-clinical HCM mutation carriers and clinical HCM<br /><br>patients) with 1) a baseline troponin concentration above the upper reference<br /><br>limit (the 99th percentile) of the high-sensitivity troponin assay that will be<br /><br>used, and 2) a troponin rise after exercise testing (more than or equal to 20%<br /><br>of the baseline concentration) using the same high sensitivity-troponin assay.</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath